首页> 外文期刊>Clinical ophthalmology >Long-term follow-up of patients with choroidal neovascularization due to angioid streaks
【24h】

Long-term follow-up of patients with choroidal neovascularization due to angioid streaks

机译:因血管纹形成脉络膜新生血管的患者的长期随访

获取原文
           

摘要

Background: The following case series describes the long-term anatomical and functional outcome of a group of seven patients with choroidal neovascularization (CNV), secondary to angioid streaks (AS), who were treated with antiangiogenic drugs in a pro re nata (PRN) regimen. After the 4-year mark, visual acuity tends to return to pretreatment level. Treatment delays and lack of aware-ness and self-referral by the patients are believed to be the cause of the PRN regimen failure. Purpose: To assess the long-term outcomes (>4 years) of patients with CNV due to AS treated with a PRN regimen of antiangiogenic. Methods: This was a retrospective, case series, single-center study. We reviewed the electronic medical records from patients with CNV due to AS. From each record, we noted general demographic data and relevant medical history; clinical presentation, changes in best-corrected visual acuity (BCVA) over time, optical coherent tomography parameters, treatment and retreatment details, and systemic associations. Changes in BCVA and central macular thickness were assessed with a Wilcoxon two-sample test, with an alpha value of?≤0.05 for statistical significance. Results: The mean follow-up time was 53.8±26.8 months. BCVA at baseline was: 1.001±0.62 logMAR; at the end of follow-up: 0.996±0.56 logMAR ( P =0.9). Central macular thickness at baseline was: 360.85±173.82 μm; at the end of follow-up: 323.85±100.34 μm ( P =0.6). Mean number of intravitreal angiogenic drugs: 6±4.16 injections (range 4–15). Mean time between injections was 3.8±2.7 months (range 1.9–5.8 months). Conclusion: Despite initial anatomical and functional improvement, patients at the end of the follow-up had no visual improvement after a pro re nata regimen of antiangiogenic drugs. The amount of retreatments, number of recurrences, and time between intravitreal injections were similar to previous reports with shorter follow-up.
机译:背景:以下病例系列描述了七名脉络膜新生血管(CNV)继发于脉络膜条纹(AS)的脉络膜新生血管(CNV)患者的长期解剖学和功能结局,他们接受了前列腺癌(PRN)中的抗血管生成药物治疗养生。 4年后,视力倾向于恢复到治疗前的水平。治疗延迟以及患者缺乏知觉和自我推荐被认为是PRN方案失败的原因。目的:评估使用抗血管生成PRN方案治疗的AS所致CNV患者的长期结局(> 4年)。方法:这是一项回顾性病例系列单中心研究。我们审查了由于AS而导致CNV患者的电子病历。从每个记录中,我们记录了总体人口统计数据和相关病史;临床表现,最佳矫正视力(BCVA)随时间的变化,光学相干断层扫描参数,治疗和再治疗细节以及系统性关联。 BCVA和黄斑中心厚度的变化用Wilcoxon两样本检验进行评估,其α值≤0.05,具有统计学意义。结果:平均随访时间为53.8±26.8个月。基线时的BCVA为:1.001±0.62 logMAR;随访结束时:0.996±0.56 logMAR(P = 0.9)。基线处的中央黄斑厚度为:360.85±173.82μm。随访结束时:323.85±100.34μm(P = 0.6)。玻璃体内血管生成药物的平均数量:注射6±4.16(范围4-15)。两次注射之间的平均时间为3.8±2.7个月(1.9-5.8个月)。结论:尽管最初的解剖学和功能有所改善,但在随访末期患者在抗血管生成药物的推荐治疗后仍无视觉改善。再治疗的次数,复发次数和玻璃体内注射之间的时间与以前的报道相似,但随访时间较短。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号